Alcohol Use Disorder (AUD)
Alcohol use disorder is where psychedelics have their strongest single result in addiction: a 2022 double-blind trial found that psilocybin plus psychotherapy roughly halved heavy drinking compared with an active placebo. It is a genuine landmark, but it is still one positive Phase 2 trial, and two further double-blind psilocybin trials in 2025 were less encouraging, one finding no benefit. Ketamine has a real abstinence signal, and LSD has famous but dated 1960s evidence. The promise here is real and the best in the addiction field, but not yet settled.
How are psychedelics being studied for alcohol use disorder? Alcohol use disorder involves difficulty controlling drinking despite harm, and relapse is common after standard treatment. The most developed psychedelic research uses psilocybin in a small number of supervised sessions with psychological support, where an early controlled trial reported fewer heavy-drinking days compared with placebo. Older work with LSD, reassessed in modern reviews, pointed in a similar direction. The idea is that a supported session may help people reset entrenched habits, with the therapy around it central to the result. The evidence is still early, samples are modest, and keeping people in follow-up to measure lasting change is difficult. Blossom tracks the trials and papers behind alcohol use research so you can read the evidence directly.
Data updated
Key Insights
- 1
Alcohol use disorder is the best-evidenced addiction indication for classic psychedelics: a 2022 double-blind randomised trial (n=93) found psilocybin-assisted therapy cut heavy drinking days to 9.7% versus 23.6% on active placebo, a genuine landmark result.
- 2
But it is still a single positive Phase 2 trial with no Phase 3 and no clean replication. Two further double-blind psilocybin trials reported in 2025, one found no benefit, and the other had its blinding broken for almost every participant.
- 3
Ketamine has its own real signal: the KARE trial (n=96) found more days abstinent at six months with ketamine plus therapy, though it did not change the relapse rate.
- 4
LSD has the most famous historical evidence, a meta-analysis of six 1950s and 1960s trials (536 patients) showing a benefit from a single dose, but the effect had faded by one year and the trials were methodologically dated.
- 5
Across every compound the psychotherapy is doing a lot of the work, blinding is hard because the drug effects are obvious, and the trials are small, so the honest reading is real promise that still needs confirmation.
By the numbers
- 46
- Trials tracked
- 111
- Papers tracked
- 3,214
- Trial participants
as of June 2026
as of June 2026
as of June 2026
Questions & Answers
The questions readers most often ask about Alcohol Use Disorder (AUD), answered with the data Blossom tracks.
Does psilocybin help with alcohol use disorder?
An early controlled trial reported fewer heavy-drinking days with psilocybin plus psychological support compared with placebo, but the evidence is still early. Blossom tracks the trials.
How is psilocybin given for alcohol use disorder?
In a small number of supervised sessions paired with psychotherapy, not as a daily medicine. Blossom lists the trials and protocols.
What is Alcohol Use Disorder (AUD)?
Alcohol use disorder (AUD) is the medical term for a persistent, harmful pattern of drinking, ranging from mild to severe, in which a person keeps drinking despite clear damage to their health, relationships or work, often with craving, tolerance and withdrawal. It is one of the most common and most damaging health conditions in the world: the World Health Organization estimates that around 400 million people live with alcohol use disorders, and alcohol is linked to about 2.6 million deaths a year[1].
It is also stubbornly hard to treat. Approved medicines help some people but have modest effects, relapse is common, and many people never engage with treatment at all. That large unmet need, combined with a striking early result, is why alcohol use disorder has become the leading test case for psychedelic-assisted therapy in addiction, and the indication where the evidence is furthest along.
This page is scoped to alcohol specifically. It sits within Blossom’s broader Substance Use Disorders hub, which covers the shared mechanisms and the evidence across other substances such as tobacco and opioids; here the focus is on what the alcohol-specific trials actually show.
Current Treatments
Standard care for alcohol use disorder combines psychological and social support, motivational and cognitive behavioural therapies, mutual-aid groups such as Alcoholics Anonymous, with medically supervised withdrawal where needed and three main approved medicines: naltrexone, acamprosate and disulfiram. These genuinely help, but their average effects are modest, adherence is often poor, and a large proportion of people relapse, which is the gap the newer approaches are trying to fill.
The psychedelic approach is different in shape: not a daily medicine but one or two supervised dosing sessions wrapped inside a course of structured psychotherapy, aiming for a lasting shift rather than ongoing symptom suppression. None of the compounds on this page is approved for alcohol use disorder anywhere; they are investigational, studied in clinical trials. What makes alcohol notable is that, unlike most psychedelic indications, it already has a positive double-blind trial behind it.
This report summarises what Blossom’s database shows about psychedelic and dissociative compounds for alcohol use disorder, and what it does not show. The short version: alcohol is the strongest case in the addiction field. It has the single best result, a positive double-blind psilocybin trial, plus genuine ketamine evidence and famous historical LSD data. But it is also a field where the most recent, better-controlled trials have been more sobering, and the honest position is real, leading promise that still awaits confirmation.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. None of the compounds discussed is approved for alcohol use disorder; they are investigational and studied only in clinical trials with intensive psychological support and medical screening. Alcohol use disorder is a serious, treatable condition, and effective help, including approved medicines and psychotherapy, is available now through health services. Withdrawal from heavy drinking can be medically dangerous and should never be attempted with a psychedelic; decisions about treatment belong with a qualified clinician.
This page sits within Blossom’s Substance Use Disorders hub and is scoped to alcohol specifically. The shared mechanisms and the evidence in tobacco, opioids and stimulants are covered there; here the focus is the alcohol-specific trials. A word on the numbers: Blossom tracks 113 papers and 46 trials tagged to this topic, and those counts appear on the page. The tag is leaky, pulling in general-addiction reviews and off-target studies (tobacco, opioids, PTSD, depression), so the genuinely alcohol-specific clinical core is smaller, roughly two dozen human studies. Read the counts as breadth of coverage, not as the size of the alcohol evidence base.
Psilocybin: the field’s strongest single result
The reason alcohol stands out is one trial. In 2022, a double-blind randomised controlled trial (95 randomised, 93 analysed) compared two psilocybin sessions with an active placebo (diphenhydramine), both wrapped in 12 weeks of psychotherapy, and found that psilocybin reduced the percentage of heavy drinking days to 9.7%, against 23.6% for placebo, a difference of 13.9% over the 32-week follow-up[1]. That is the first positive double-blind trial of a classic psychedelic for any addiction, and it followed an open-label pilot in which abstinence rose specifically after psilocybin was given[2].
It deserves to be taken seriously, and it deserves its asterisks. It is a single Phase 2 trial at two centres with around ninety patients, and 2025 brought two more double-blind psilocybin alcohol trials that did not simply confirm it. A Swiss trial of a single dose given after withdrawal found no benefit over placebo[3], and a French feasibility trial in patients with co-occurring depression reported higher abstinence (55% versus 11%) but acknowledged its blinding had failed for over 90% of participants[4]. A separate open-label single-dose study did report large reductions in heavy drinking[5], but without a control group. The pattern suggests the effect is real but sensitive to dose, number of sessions, the therapy and the population, which is exactly why replication matters.
Ketamine: a real, more modest signal
Ketamine, a dissociative anaesthetic rather than a classic psychedelic, has the second-strongest evidence. The KARE trial (n=96) found that three ketamine infusions plus relapse-prevention therapy produced significantly more days abstinent at six months than placebo, a difference of about 10%, and about 16% for the full ketamine-plus-therapy combination versus saline plus education[6]. An earlier pilot (n=40) found a single infusion increased abstinence and delayed relapse[7].
The honest qualifications are that KARE improved days abstinent but not the relapse rate, the samples are proof-of-concept size, and ketamine acts briefly, so it implies a repeated, supervised, therapy-paired model rather than a single cure. A telling detail connects it to the classic psychedelics: a reanalysis found ketamine’s benefit on drinking was carried by the intensity of the mystical-type experience, not by dissociation[8]. Whatever the receptor pharmacology, the psychological character of the session seems to matter across these very different drugs.
LSD: famous history, dated evidence
LSD’s link to alcoholism is the oldest story in the field; in the 1950s and 1960s it was one of LSD’s main psychiatric uses. The modern summary is a 2012 meta-analysis that pooled six randomised trials from that era (536 patients) and found a single LSD dose reduced alcohol misuse, with an odds ratio of 1.96 and remarkably consistent results across trials[9]. For a treatment given decades before modern trial standards, that is a striking and genuine signal.
But it must be read in context. Those trials used single doses, often imperfect blinding and inconsistent outcome measures; a contemporary re-analysis judged four of the six at high risk of bias[10], and the benefit in the original meta-analysis had faded by one year. A modern, properly controlled LSD alcohol trial is now under way but has not reported. So the LSD evidence is historically important and points the same way as the newer work, without itself meeting today’s bar for proof.
MDMA, 5-MeO-DMT and others: early signals
The remaining compounds are earlier still. MDMA-assisted therapy for alcohol use disorder rests on an open-label safety study (n=14) in which drinking was much lower nine months after detox[11], encouraging but uncontrolled; its more promising use may be where alcohol problems and post-traumatic stress overlap. Inhaled 5-MeO-DMT reported a striking open-label phase 2a result, with abstinent days rising from 33% to 81% by week 12[12], again without a control group. Ayahuasca and ibogaine appear mainly in preclinical and observational work for alcohol, with no controlled human trial in the database.
The common thread is that beyond psilocybin, ketamine and the historical LSD data, the alcohol evidence is open-label, observational or preclinical. Large open-label effects are the norm in this field and routinely shrink under blinding, so these should be read as reasons to run controlled trials, not as results in their own right.
How might these work?
The proposed mechanisms are plausible and still partly hypotheses. The classic psychedelics act on the brain’s 5-HT2A serotonin receptors and appear to open a window of heightened neuroplasticity, which, paired with psychotherapy, may help loosen entrenched habits and the rumination and hopelessness that sustain heavy drinking. Ketamine works through a different receptor (blocking NMDA) but seems to reach a similar place, a burst of plasticity and a meaningful psychological experience. Across both, reduced craving, greater psychological flexibility and the subjective depth of the session keep emerging as the active ingredients, which is why the therapy around the drug is treated as part of the treatment, not an optional extra.
Durability, blinding and the psychotherapy question
Three practical issues run under all of this and shape how the results should be read. The first is durability: the LSD meta-analysis benefit faded by a year, ketamine acts only briefly, and even psilocybin’s single-dose model has not been followed long enough across trials to know how long the effect lasts or whether it needs repeating. The second is blinding. A high dose of a psychedelic is unmistakable, so participants usually know which arm they are in, and the 2025 French trial showed this starkly with blinding failing for over ninety per cent of patients. That expectancy almost certainly inflates the apparent drug effect, and it is the central methodological problem the field has yet to solve.
The third is the psychotherapy itself. In every positive trial the drug is given inside an intensive course of structured therapy, with preparation and integration sessions, and the largest ketamine effect was specifically the combination of drug plus therapy. It is genuinely unresolved how much of the benefit is pharmacological and how much is the psychological scaffolding, and that question matters enormously for how, and whether, any of this could be delivered at scale outside a research setting. None of this erases the signal, but it does mean the honest unit of treatment here is "drug plus therapy in a supervised container", not a pill.
Reading this honestly
So where does alcohol use disorder sit? At the front of the addiction field, and that lead is real: it has the one positive double-blind psychedelic addiction trial, a genuine ketamine signal, and a deep historical literature all pointing the same way. It is also a cautionary tale in progress. The most rigorous recent trials have been mixed, blinding is a serious unsolved problem, the samples are small, and the psychotherapy is doing a great deal of the work. The honest conclusion refuses both the hype that treats alcohol as solved and the cynicism that dismisses a striking, replicated-in-spirit body of evidence. For a condition that harms hundreds of millions of people and is poorly served by existing treatments, a leading but unconfirmed signal is genuinely hopeful, and the confirmatory trials now running will decide how much of that hope holds.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Alcohol Use Disorder (AUD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin The flagship: a 2022 double-blind RCT (n=93) cut heavy drinking days to 9.7% vs 23.6% on active placebo. But it is a single positive Phase 2 with no Phase 3, and two 2025 double-blind trials were mixed (one null, one with broken blinding), so the result is real but not yet replicated. | Large | Moderate | Moderate |
| Ketamine The KARE trial (n=96) found more days abstinent at six months with ketamine plus therapy (mean difference about 10%), and a smaller pilot delayed relapse. But it did not reduce the relapse rate itself, the effect is short-acting, and it is proof-of-concept scale. | Medium | Moderate | Moderate |
| LSD A meta-analysis of six 1950s-70s RCTs (536 patients) found a single LSD dose reduced alcohol misuse (odds ratio 1.96). The trials were consistent but methodologically dated and high risk of bias, and the benefit had faded by one year. No completed modern trial yet. | Medium | Low | Moderate |
| MDMA Only an open-label safety study (n=14) of MDMA-assisted therapy after detox, which reported much lower drinking at nine months. With no control group and a tiny sample it is a hypothesis, not evidence of efficacy. Now being tested mainly for co-occurring alcohol use and PTSD. | Medium | Very Low | Low |
Psilocybin and Alcohol Use Disorder (AUD)
Psilocybin is the reason alcohol use disorder is the standout addiction indication. In 2022, a double-blind randomised trial (95 randomised, 93 analysed) found that two psilocybin sessions plus psychotherapy reduced heavy drinking days to 9.7%, versus 23.6% with an active placebo (diphenhydramine), a mean difference of 13.9% over 32 weeks[1], with no serious adverse events. It was preceded by an open-label pilot (n=10) in which abstinence rose only after dosing and largely held to 36 weeks[2].
The honest update is that 2025 complicated the picture. A Swiss double-blind trial of a single dose after withdrawal (n=37) found no benefit over placebo[3], while a French feasibility trial reported higher abstinence (55% vs 11%) but had its blinding broken for over 90% of patients[4]. So psilocybin has the best result in the field and a real signal, but it is one positive Phase 2 amid mixed newer data, not a settled treatment.
Ketamine and Alcohol Use Disorder (AUD)
Ketamine has its own genuine, if more modest, evidence. The KARE trial (n=96) found that ketamine infusions plus relapse-prevention therapy produced significantly more days abstinent at six months than placebo (mean difference about 10%, rising to about 16% for ketamine plus therapy versus saline plus education)[1], and an earlier pilot (n=40) found a single infusion increased abstinence and delayed relapse[2].
Two caveats keep this in proportion. KARE found no significant difference in the relapse rate itself, only in days abstinent, and ketamine’s effects are short-acting, so it points toward a repeated, supervised, therapy-paired treatment rather than a one-off cure. Intriguingly, a reanalysis found ketamine’s effect on drinking was carried by the intensity of the mystical-type experience, not by dissociation[3], echoing the psychedelics and underlining how much the psychological experience matters.
LSD and Alcohol Use Disorder (AUD)
LSD has the longest history of any compound here: treating alcoholism was one of the main uses of LSD in 1950s and 1960s psychiatry. A 2012 meta-analysis pooled six of those randomised trials (536 patients) and found a single LSD dose reduced alcohol misuse, with an odds ratio of 1.96[1], and the trials were notably consistent with each other.
The caveats are equally important. Those trials were single-dose, often single-blind, methodologically dated, and a modern re-analysis judged four of six at high risk of bias[2]; the benefit also faded by one year. A modern LSD alcohol trial is under way but has not reported. So LSD’s alcohol story is historically important and genuinely positive, but it is old evidence that today’s standards would not treat as conclusive.
MDMA and Alcohol Use Disorder (AUD)
MDMA for alcohol use disorder is at a much earlier stage. The main data is an open-label safety study (n=14) in which MDMA-assisted therapy after detox was associated with much lower drinking at nine months (about 19 units a week versus 131 before)[1]. It was well tolerated, but with no control group and only 14 people it cannot show that MDMA itself caused the change.
The more promising direction for MDMA may be the common overlap between alcohol problems and post-traumatic stress, where MDMA-assisted therapy is now being tested for both at once. For alcohol use disorder on its own, though, the honest status is an encouraging open-label signal that needs a controlled trial before it means anything. Newer agents such as inhaled 5-MeO-DMT have reported striking open-label numbers too, with the same caveat.
Clinical Outlook
The near-term question is whether the 2022 psilocybin result replicates. A larger, properly powered Phase 2 or Phase 3 confirmation is the obvious next step[1], and the mixed 2025 read-outs make that confirmation more important, not less: they suggest the effect may depend heavily on dose, the number of sessions, the psychotherapy, and how blinding is handled. Meanwhile ketamine-assisted approaches are moving toward larger trials, and a modern LSD trial and several head-to-head psilocybin-versus-ketamine studies are running.
The realistic outlook is cautious optimism. Alcohol use disorder has the strongest hand in the addiction field, a positive double-blind trial, a plausible mechanism, and a large unmet need, but it is one good result, not a proven therapy, and the newer data is a useful reminder that early breakthroughs in this field often shrink on replication. If the confirmatory trials hold, psychedelic-assisted therapy could become a real option for a condition badly in need of better ones; if they do not, alcohol will have been an important test of how much of the early promise survives proper scrutiny.
Industrial Landscape
Alcohol use disorder attracts an unusually academic and public-sector research base, led by university groups such as those at NYU and Johns Hopkins that ran the foundational psilocybin trials, and UK academic teams behind the ketamine and MDMA work. Much of the funding has come from research institutes and non-profits rather than a single dominant developer, which has kept the work relatively measured.
On the commercial side, a number of companies are active around alcohol and the wider addiction space, including firms developing ketamine-assisted therapy and short-duration psychedelics, but the field is fragmented and has seen the usual churn of small biotech. Because alcohol use disorder is a large market with cheap existing generics and modest reimbursement, the commercial case is less obvious than in depression, which is part of why the running is still made largely by academics.
For an honest broker, that academic centre of gravity is a strength: the alcohol evidence base is among the most rigorous in psychedelic medicine, with a real double-blind trial and openly published null and mixed results. The willingness to report the 2025 disappointments alongside the 2022 success is exactly the kind of transparency the field needs more of.
Quick Indicators
Related Topics
Organisations
Search →Clerkenwell Health
UK psychedelic and CNS trial infrastructure provider with specialist trial sites, sponsor-facing psychiatric research support, recruitment pathways, and therapist-related trial expertise.
Exeter University
The University of Exeter is a public research university based in Exeter, Devon, England, with additional campuses in Cornwall. It provides undergraduate and postgraduate education and conducts research across a wide range of disciplines.
University of Exeter
The University of Exeter is a public research university located in Exeter, England. It operates multiple campuses including Streatham and St Luke’s in Exeter and a campus at Penryn in Cornwall.
AtaiBeckley
AtaiBeckley Inc. is a clinical-stage biotechnology company formed in 2025 through the strategic combination of atai Life Sciences and Beckley Psytech. It operates as a public company focused on developing rapid-acting, durable, and convenient mental health treatments, with a strong psychedelic-therapeutics emphasis. Its principal executive office is in New York, New York, United States. AtaiBeckley matters in the psychedelic ecosystem because it combines clinical development capabilities with a public-market platform that can support late-stage psychedelic drug programs. Public disclosures describe pipeline work that includes BPL-003 and note that the company’s psychedelic-based therapies are being advanced through the Beckley Psytech strategic investment and later combination.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
University of Sydney
The Brain and Mind Centre is advancing psychedelic science with a multidisciplinary focus on developing innovative treatments using AI and preparing for human clinical trials to treat severe mental illness.
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
University of Zurich
Within the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
Geneva University Hospital
One of Europe's foremost centres for psychedelic-assisted therapy, operating within Switzerland's compassionate use framework. Under Professor Daniele Zullino, HUG treats depression and PTSD with psilocybin, LSD, and MDMA, and hosts one of five university-affiliated psychedelic research laboratories in Switzerland.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation headquartered in Madison, Wisconsin. Usona develops and supports clinical research on psilocybin and other consciousness-expanding medicines with a mission-driven access model. Its psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study, Usona launched the Phase 3 uAspire trial in 2024, a 240-participant randomised, double-blind multicentre study of 25 mg psilocybin with psychosocial support for adults with MDD. In April 2026, industry reporting said Usona confirmed it had received an FDA Commissioner National Priority Voucher for psilocybin in MDD, potentially shortening review if an NDA is filed and accepted. Usona is also exploring 5-MeO-DMT in early-stage research.
Monash University
The Clinical Psychedelic Lab, led by Dr. Paul Liknaitzky, conducts robust clinical trials exploring the efficacy and safety of psychedelic-assisted therapies for various mental health conditions within the Australian healthcare context.
People
Search →Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Marta Torrens
Professor of Psychiatry and former Director of the Addictions Department at Hospital del Mar; Group Leader in Addictions at Hospital del Mar Research Institute (IMIM)
She is a leading Spanish addiction psychiatrist whose human pharmacology and clinical research on substances like MDMA, mephedrone, methylone, 2C-B, and LSD has informed psychedelic and novel psychoactive substance science.
Anna Ermakova
Research Scientist at Beckley Psytech and psychedelic research contributor
She is an author on multiple influential 5-MeO-DMT clinical and review papers, helping build the evidence base for psychedelic therapies in depression and alcohol use disorder.
Dalibor Sames
Professor of Chemistry at Columbia University
He is a leading medicinal/organic chemist whose group has helped define the pharmacology and synthetic development of ibogaine and iboga analogs in psychedelic and neurotherapeutic research.
Edward Nunes
Professor of Psychiatry at Columbia University Irving Medical Center
A leading addiction psychiatrist whose clinical trials helped establish ketamine as a promising intervention for cocaine and alcohol use disorders.
Carl Hart
Mamie Phipps Clark Professor of Psychology (in Psychiatry) at Columbia University
He is a leading researcher on human psychopharmacology and substance use disorders, including ketamine and other psychoactive drugs, with influential work on drug self-administration and treatment models.
Ruben Laukkonen
Director of the Flourishing Intelligence Program at the University of Oxford; Senior Researcher in Oxford’s Psychiatry Department
He is a cognitive scientist whose work connects insight, meditation, and psychedelic states, and he co-authored several influential papers on insight and psychedelics.
Lindsey Owens
Research coordinator and doctoral trainee in medical/clinical psychology; psychedelic-assisted therapy researcher
She is notable for coauthoring and supporting several key psilocybin-assisted psychotherapy studies on alcohol use disorder, including clinical, qualitative, and case-report papers.
Connected Evidence
The latest clinical data and verified academic findings associated with Alcohol Use Disorder (AUD).